Clinical trials

Condition   Drug Name  
Study Azacytidine in dermatosis
Patients 1
Treatment Regimen Azacytidine, 75 mg/m2 s.c. x 7 d 1x/28 d
Conclusions Azacytidine induced resolution of cutaneous lesions with complete bone marrow remission in a patient with myelodysplastic syndrome
Reference(s) Complete response of deep neutrophilic dermatosis associated with myelodysplastic syndrome to 5-azacytidine
Br J Dermatol 2007, 156 (5):1039.
Author and Affiliation Raj, K., Ho, A., Creamer, J.D., du Vivier, A.W., Salisbury, J.R., Mufti, G.J.